Apolipoprotein-E Controls Adenosine Triphosphate-Binding Cassette Transporters ABCB1 and ABCC1 on Cerebral Microvessels After Methamphetamine Intoxication

Ayman ElAli, PhD; Andrés Urrutia, MSc; Ana Rubio-Araiz, PhD; Macarena Hernandez-Jimenez, PhD; Maria I. Colado, PhD; Thorsten R. Doeppner, MD, MSc; Dirk M. Hermann, MD

Background and Purpose—Methamphetamine is a powerful addictive, which has been associated with ischemic stroke and brain hemorrhage in humans. Whether and how methamphetamine influences the expression of tight junctions and adenosine triphosphate-binding cassette transporters, which have previously been shown to be regulated by apolipoprotein-E (ApoE) under conditions of brain ischemia, was unknown.

Methods—C57BL/6J mice received intraperitoneal injections of methamphetamine (3 times 4 mg/kg separated by 3 hours) either alone or in combination with the ApoE receptor-2 inhibitor receptor-associated protein (40 μg/kg) or the inducible nitric oxide synthase inhibitor 1400W (5 mg/kg). Animals were euthanized 3 or 24 hours after methamphetamine exposure. Tissue responses were evaluated with Western blots, immunoprecipitation, and immunohistochemistry using total brain and cerebral microvessel extracts.

Results—Methamphetamine induced a transient activation of stress kinases c-Jun N-terminal kinase 1/2 and p38 in the brain parenchyma and increased intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression on cerebral microvessels without inducing loss of tight junction proteins and without inducing IgG extravasation. Methamphetamine transiently increased the expression of the luminal adenosine triphosphate-binding cassette transporter ABCB1 on cerebral microvessels and reduced the expression of the abluminal transporter ABCC1. Elevated expression of ApoE was noted in the brain parenchyma by methamphetamine, activating ApoE receptor-2 on brain capillaries, deactivating c-Jun N-terminal kinase 1/2 and c-Jun, and regulating ABCB1 and ABCC1 expression. Indeed, ApoE receptor-2 and inducible nitric oxide synthase inhibition prevented the ABCB1 and ABCC1 expression changes.

Conclusions—Acute exposure to methamphetamine at doses comparable to those consumed in drug addiction does not induce tight junction breakdown but differentially regulates adenosine triphosphate-binding cassette transporters through the ApoE/ApoE receptor-2/c-Jun N-terminal kinase 1/2 pathway. (Stroke. 2012;43:1647-1653.)

Key Words: apolipoprotein-E receptor-2 ■ blood–brain barrier ■ c-Jun N-terminal kinase 1/2 ■ drug abuse ■ endothelium ■ multidrug resistance ■ neuropathology ■ signal transduction ■ tight junction

Methamphetamine (also called crystal meth or meth) is a psychostimulant and addictive that causes severe health problems mainly due to neurotoxicity, cardiac arrhythmia, and hyperthermia.1,2 In the brain, meth overactivates the dopaminergic system, disrupting synaptic integrity3 and inducing neuronal injury through oxidative stress.4,5 Meth may also induce neuroinflammation6–7 and increase blood–brain barrier (BBB) permeability.8,9 Possibly related to such vascular actions, meth abuse has been shown to be associated with ischemic stroke and intracerebral and subarachnoid hemorrhage in humans.10

The BBB is formed by endothelial cell–cell contacts, the tight junctions,11 which are complemented by transporters on the luminal and abluminal endothelial membranes belonging to the adenosine triphosphate-binding cassette (ABC) transporter and solute carrier families.12,13 Whereas tight junctions are responsible for maintaining paracellular BBB tightness, ABC transporters control brain homeostasis and protect the brain from environmental molecules by eliminating them across the BBB.12,13 In vitro, meth exposure has previously been shown to deregulate tight junction proteins14–16 and impair the expression of a solute carrier, the glucose trans-
porter protein-1. In vivo, the effect of meth on tight junction integrity and ABC transporter expression was unknown. Meth has previously been proposed to act as an ABC transporter substrate.

ABC transporters are actively regulated in the brain under various pathophysiological conditions. In focal cerebral ischemia, our group has previously shown that the transporter ABCB1 (previously: multidrug resistance transporter-1), which is localized on the luminal membrane of brain endothelial cells and extrudes a broad range of substrates—among them also pharmacological drugs—from the vessel into the blood, is upregulated, whereas the transporter ABCC1 (previously: multidrug resistance-associated protein-1), which is expressed on the abluminal endothelial membrane and carries its substrates—among them various cell metabolites—in the opposite direction from the vessel into the brain, is downregulated on cerebral microvessels. ABCB1 and ABCC1 expression were controlled by apolipoprotein-E (ApoE), which deactivates c-Jun N-terminal kinase-1/2 (JNK1/2) and its downstream kinase c-Jun through its receptor ApoER2 (also: low-density lipoprotein receptor-related protein-8), thereby modulating ABC transporter transcription.

Based on these earlier results, we were interested in how an acute meth exposure at doses comparable to those used in drug addiction influences the integrity of tight junctions and ABC transporter expression on brain capillary cells. A deregulation of tight junctions might be relevant with respect to stroke pathogenesis, because it may reveal a mechanism by which meth may provoke cerebral thromboembolism and brain hemorrhage. The regulation of ABC transporters, on the other hand, might unravel a strategy through which the brain protects itself from intoxication.

Materials and Methods

Animal Groups and Methamphetamine Exposure

All animal experiments were done according to the National Institutes of Health guidelines for the care and use of laboratory animals based on guidelines of the local Animal Welfare Committee of the Universidad Complutense de Madrid. Adult male C57BL/6j mice (Harlan, Barcelona, Spain) weighing 25 to 30 g were kept under conditions of constant ambient temperature (21±2°C) at a 12-hour light/dark cycle (lights on at 8:00 AM) with free access to food and water. Meth (4 mg/kg, dissolved in 0.9% NaCl; Sigma, Madrid, Spain) or vehicle (0.9% NaCl) was intraperitonetally administered 3 times at 3-hour intervals. A first set of mice was divided into 3 groups receiving (1) vehicle treatment followed by 3 hours survival starting with the last injection (n=7 animals); (2) meth treatment followed by 3 hours survival (n=8); or (3) meth treatment followed by 24 hours survival (n=8). Animals were euthanized by cervical dislocation at the indicated times.

To elucidate the role of ApoER2 and cytosolic signals in the regulation of ABC transporters and BBB integrity, a second set of mice received (1) vehicle injections (n=5); (2) meth injections (n=5), (3) meth injections combined with the ApoER2 inhibitor receptor-associated protein (RAP; 40 µg/kg; Biovial, Dublin, OH) that was intraperitoneally administered on occasion of the last injection; this dose inhibits low-density lipoprotein receptor-related protein-8 without blocking low-density lipoprotein receptor and does not influence lipid metabolism (n=5); or (4) meth injections combined with the inducible nitric oxide synthase (iNOS) inhibitor 1400W (5 mg/kg; Sigma) that was intraperitoneally administered on occasion of each of the 3 meth injections (n=5). During the study, rectal temperature was measured with a rectal sonde. To test effects of pharmacological inhibitors alone in the absence of meth, additional mice received injections of (1) vehicle (n=4); (2) RAP (40 µg/kg; n=4); or (3) 1400W (5 mg/kg; n=4). Animals were euthanized 3 hours after the last injection. Brain cryostat sections were prepared at the level of the midstriatum (+0.8 mm of bregma) that were used for hematoxylin and eosin staining. The remaining striatum was dissected on ice.

To evaluate changes in arterial blood pressure, a third set of mice was anesthetized with urethane (1 g/kg, intraperitoneally) and placed on a homeothermic blanket (Harvard Apparatus). Urethane was chosen as anesthetic because among all known anesthetics urethane has least effects on blood pressure. After systemic intraperitoneal delivery of urethane at doses comparable to those used previously, no changes in blood pressure have been reported. Mean arterial blood pressure was recorded using a Laboratory-Trax-4/24F system (World Precision Instruments) through a polyethylene catheter that was implanted into the right femoral artery. One subset of animals was anesthetized 30 minutes before the first (1 vehicle (n=4); or (2) meth (n=5) injection. In these animals blood pressure values were taken at 6-minute intervals before and after each vehicle or meth injection over a duration of 30 minutes, resulting in a total of 5 measurements on occasion of each treatment. These animals were euthanized after the last recording on that same day. To examine longer-lasting effects of meth exposure, an additional subset of animals received 3 consecutive treatments with (1) vehicle (n=4); or (2) meth (n=5). These animals were anesthetized 24 hours after the last injection. During the next 24 minutes, a total of 4 blood pressure measurements were done, of which mean values were reported.

Microvessel Isolation and Protein Extraction

For total brain homogenates, tissue samples from animals belonging to the same group were pooled (n=4–8; see previously), homogenized, and lysated in 1% NP-40 buffer containing 50 mmol/L Tris-HCl and 150 mmol/L NaCl (pH 7.4) supplemented with 5% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail-2 and sonicated. For microvessel isolation, pooled tissue samples were homogenized in microvessel isolation buffer and supplemented with 5% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail-2. Homogenates were centrifuged at 3200 rpm for 10 minutes at 4°C. The resulting pellets were resuspended in 20% dextran (molecular weight 64 000–76 000; D4751; Sigma) in microvessel isolation buffer. Suspensions were centrifuged at 6500 rpm for 20 minutes at 4°C. The resulting crude microvessel-rich pellets were resuspended in microvessel isolation buffer and filtered through 2 nylon filters of 100-µm and 30-µm mesh size (Millipore, Schwalbach, Germany). Microvessels were stored at −80°C until further use. Isolated microvessels were homogenized in appropriate lysis buffers (see subsequently) supplemented with 5% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail-2. Lysate samples were sonicated over 2 cycles lasting 20 seconds each at 4°C. Protein concentrations were measured using a Bradford assay kit with an iMark microplate reader (Bio-Rad, Hercules, CA). The microvessel fractions produced have previously been shown to exhibit a high degree of purity lacking glial fibrillary acidic protein, which is strongly expressed on astrocytic end feet.

Western Blotting

Lysates containing 20 µg protein were complemented with 5× sodium dodecyl sulfate loading buffer. Samples were pretreated by heating and processed under reducing conditions except for the ABC transporter blots, for which nonheated samples were loaded under nonreducing conditions to avoid aggregation of these highly glycosylated membrane proteins. Samples were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis followed by Western blot analysis using primary antibodies diluted 1:100 for ABCC1 and 1:1000 for all other proteins in 5% skim milk and 0.1 mol/L Tris-buffered saline containing Tween 20%. Blots were digitized, densitometrically analyzed, and corrected for protein.
loading by means of the β-actin or β-tubulin blots. Specifications of the antibodies used are given in the online-only Supplementary Materials and Methods.

Immunoprecipitation Assay
Lytes containing 800 μg protein that had been obtained using a 1% NP-40 lysis buffer containing 150 mmol/L NaCl and 50 mmol/L Tris base (pH 8.0) were supplemented with sodium orthovanadate (final concentration: 1 mmol/L) and complemented with 3 equal volumes of NET buffer (100 mmol/L Tris, 200 mmol/L NaCl, 5 mmol/L EDTA, 5% NP-40, pH 7.4). Two micrograms of anti-ApoER2 antibody (Santa Cruz Biotechnology) were added to each sample and incubated overnight at 4°C under slight rotation. The next day 20 μL of protein A/G plus-agarose was added to the samples, which were incubated 1 hour at 4°C. Finally samples were centrifuged for 30 seconds at 15 000 rpm at 4°C. Supernatants were dispersed and pellets washed 3 times in ice cold NET buffer. Twenty microliters of 2× sodium dodecyl sulfate–polyacrylamide gel loading buffer was added to each pellet and boiled for 5 minutes followed by a short centrifugation time points. Results are presented as means±SD. Probability values <0.05 were considered significant.

Results
Methamphetamine Induces a Parenchymal Stress Response
To evaluate the effect of meth administration on the brain parenchyma, we analyzed the expression and activation of 2 stress activated kinases, JNK1/2 and p38. Western blots analysis using extracts from total brain homogenates showing that (A) JNK1/2 and (B) p38 MAPK phosphorylation (ie, activation) are transiently increased in the brain parenchyma at 3 hours after methamphetamine exposure. Note that total JNK1/2 and p38, which were evaluated with antibodies detecting both the nonphosphorylated and phosphorylated kinases, are not influenced by methamphetamine. Data are means±SD (n=4 Western blots). *P<0.05/**P<0.01 compared with vehicle. JNK indicates c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase.

Methamphetamine Induces Adhesion Molecules in Cerebral Microvessels and Upregulates Tight Junction Proteins Without Provoking IgG Extravasation or Major Leukocyte Infiltration
To investigate how acute meth exposure influences vascular integrity, we studied the expression of adhesion molecules and tight junction proteins in cerebral microvessels and investigated the extravasation of the endogenous tracer IgG in total brain extracts, which upon BBB damage is able to accumulate in the brain parenchyma.21 Meth transiently induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression (Figure 2A–B) and elevated occludin and claudin-5 expression at 3 but not 24 hours in cerebral microvessels (online-only Supplemental Figure IIA–B) but did not influence zonula occludens-1 levels (not shown). No IgG extravasation was noted in the brain parenchyma using Western blots (online-only Supplemental Figure IIC). Hematoxylin–eosin stainings revealed that the macroscopical structure of cerebral microvessels remained intact after meth exposure (online-only Supplemental Figure IID). Leukocyte counts in the stria-
tum, as evaluated by CD45 immunohistochemistry, were not significantly increased by meth (online-only Supplemental Figure III).

**Methamphetamine Differentially Regulates ABCB1 and ABCC1 in Cerebral Microvessels**

We next examined how meth influences the expression of the transporters ABCB1 and ABCC1 on cerebral microvessels. Interestingly, ABCB1, which is expressed on the luminal endothelial membrane, was upregulated (Figure 3A), whereas ABCC1, which is localized on the abluminal endothelial membrane, was downregulated (Figure 3B) at 3 hours after meth intoxication. ABCB1 and ABCC1 expression returned to baseline levels within 24 hours (Figure 3A–B).

**ApoE Is Upregulated on Meth Exposure, ApoER2 Is Activated, and JNK1/2 and c-Jun Are Deactivated**

Subsequent to brain ischemia, ApoE regulates ABCB1 and ABCC1 expression in an ApoER2/JNK1/2/c-Jun-dependent way. To investigate whether ApoE influenced ABC transporters after meth intoxication, we examined ApoE expression in total brain extracts, showing that ApoE was increased at 3 hours after meth exposure (Figure 4A). Subsequent analysis of microvessel extracts revealed that ApoER2 was activated by meth through tyrosine phosphorylation (Figure 4B). Concomitantly, JNK1/2 and c-Jun were dephosphorylated (ie, deactivated; Figure 4C–D).

**Inhibition of ApoER2 and JNK1/2’s Effector iNOS Re-Establish ABC Transporter Expression**

To test whether ApoER2 was indeed responsible for mediating ABC transporter responses to meth exposure, we administered a pharmacological inhibitor of ApoER2, RAP, and an inhibitor of iNOS, 1400W. The iNOS inhibitor was chosen, because iNOS has previously been shown to act as effector of JNK1/2. We found that either RAP or 1400W administration re-established ABCB1 and ABCC1 expression (Figure 5A–B) at the same time restoring JNK1/2 and c-Jun phosphorylation (Figure 5C–D). Rectal temperature was not influenced by RAP and 1400W (online-only Supplemental Figure I). RAP or 1400W alone did not change the expression of ABCB1 or ABCC1 (online-only Supplemental Figure IV).

**Discussion**

Using a mouse model of systemic meth intoxication, we show that acute exposure to meth at doses comparable to those used in drug addiction (doses ingested by consumers are typically in the range of 50–500 mg) induces a transient parenchymal stress response, reflected by the activation of JNK1/2 and p38 mitogen-activated protein kinase, accompanied by the induction of proinflammatory cell adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 on cerebral microvessels. Although tight junction proteins occludin, claudin-5, and zonula occludens-1 were expressed at a high level and microvascular permeability for the serum marker IgG was low, a differential regulation of ABC transporters, namely an upregulation of the luminal endothelial transporter ABCB1 and downregulation of the abluminal transporter ABCC1, was observed on cerebral microvessels, which, as we showed, was controlled by ApoE, most probably through its receptor ApoER2 that deactivated the JNK1/2/c-Jun pathway.

Cerebrovascular effects of meth have already been described previously. In rats and mice, acute meth exposure resulted in an increased permeability to endogenous and
However, such actions were observed at doses far above those consumed in drug addition associated with massive hyperthermia to more than 41.5°C suggesting subsequent lethality, whereas such changes were markedly attenuated under conditions of more subtle hyperthermia. In addition, acute rises in arterial blood pressure lasting over several minutes were found after delivery of higher meth doses. In 1 of those studies delivering meth at doses of 30 mg/kg, a decreased expression of the tight junction proteins occludin, claudin-5 and zonula occludens-1 was noted in the mouse hippocampus 24 hours after exposure. We did not detect arterial blood pressure changes in the current study, and rectal temperature changes were only transient. We observed an elevated expression of occludin and claudin-5 and an unchanged expression of zonula occludens-1. IgG extravasation was low. Despite absence of overt BBB breakdown, a differential regulation of ABC transporters was noted on cerebral microvessels. The luminal ABCB1, which carries its substrates in direction from the vessel into the blood, was upregulated,

**Figure 4.** Methamphetamine increases ApoE expression, activating ApoER2 and deactivating JNK1/2 and c-Jun in cerebral microvessels. Western blot analysis and immunoprecipitation studies using total brain (A) and cerebral microvessel (B-D) extracts showing that (A) ApoE is upregulated in the brain parenchyma by methamphetamine, activating (B) ApoER2 on brain capillaries through tyrosine phosphorylation and deactivating (C) JNK1/2 and (D) c-Jun by dephosphorylation. Note that total JNK1/2 and c-Jun are again not influenced by methamphetamine. Data are means ± SD (n = 4 Western blots). *P < 0.05; **P < 0.01 compared with vehicle. ApoE indicates apolipoprotein-E; ApoER2, apolipoprotein-E receptor-2; JNK, c-Jun N-terminal kinase.

**Figure 5.** Inhibition of ApoER2 and iNOS re-establish ABC transporter expression. Western blot analysis using cerebral microvessel extracts showing that either the ApoER2 inhibitor RAP or the iNOS inhibitor 1400W restore (A) ABCB1 and (B) ABCC1 expression, increasing (C) JNK1/2 and (D) c-Jun phosphorylation (ie, activation). Data are means ± SD (n = 4 Western blots). *P < 0.05; **P < 0.01 compared with vehicle; †P < 0.05; ††P < 0.01 compared with methamphetamine only. ApoER2 indicates apolipoprotein-E receptor-2; iNOS, inducible nitric oxide synthase; ABC, adenosine triphosphate-binding cassette; RAP, receptor-associated protein.
whereas the abluminal ABCC1, which carries its substrates in the opposite direction from the vessel into the brain, was downregulated on brain capillary cells. The expression changes of ABC transporters were controlled by ApoE, which, as we further observed, activated its receptor ApoER2 on cerebral microvessels by tyrosine phosphorylation, thus dephosphorylating and deactivating JNK1/2 and c-Jun. We have previously shown in a model of transient focal cerebral ischemia that ApoE controls ABCB1 and ABCC1 expression on the transcriptional level through the JNK1/2/c-Jun pathway. In that study, we found that either genetic ApoE deletion or pharmacological JNK1/2 blockade prevented the physiological responses of ABC transporters. We now complemented our previous findings with pharmacological ApoER2 and iNOS inhibition data, demonstrating that the ApoE/ApoER2/JNK1/2 pathway is similarly relevant for meth intoxication. Based on our results, ApoE that is released from the brain parenchyma might act as a sensor for brain injury in a variety of pathophysiological states, transmitting stress signals to the endothelial cells through ApoER2, which as we previously reported is constitutively expressed on the abluminal endothelial membrane.

Through this ApoER2 signal, ABC transporters are regulated in a way that facilitates the removal of toxins from the brain tissue. We did not perform biodistribution experiments in the present study, yet we have previously shown in focal cerebral ischemia that alterations in ABCB1 and ABCC1 expression are accompanied by profound changes in the brain-to-blood distribution of ABC transporter substrates. ABCB1 is a broad-spectrum transporter, which binds a large variety of environmental and also pharmacological compounds. ABCB1 has previously been suggested to act as efflux transporter for meth at the murine BBB. Compared with ABCB1, ABCC1 has more restricted substrate-binding properties. ABCC1 was shown to have strong affinity to amphipathic molecules and brain metabolites among those Phase II degradation products generated as a consequence of oxidation processes. At the murine BBB, such metabolites were shown to enter the brain parenchyma across the ABCB1 transporter. Meth is extensively metabolized, generating large amounts of reactive oxygen species, including nitric oxide and peroxynitrites in the brain. These metabolites require detoxification and removal across the BBB. By upregulating the luminal ABCB1 and downregulating the abluminal ABCC1 transporter, the brain possesses an efficient detoxification mechanism. Strengthening this ABC transporter response might represent a promising strategy that might allow the prevention of meth-induced brain injury.

Acknowledgments
We thank Beate Karow for technical assistance.

Sources of Funding
Supported by the German Research Foundation (HE31732/1 and HE3173/3-1 to D.M.H.), Dr-Werner-Jackstädt Foundation (to A.E.A.), Heinz-Nixdorf Foundation (to D.M.H.), Spanish Ministry of Science and Innovation (SAF2010-21529 to M.I.C.), Plan Nacional Sobre Drogas (PR47/10-17826 to M.I.C.), Red de Trastornos Adictivos (RD06/0001/006 to M.I.C.), and UCM (910258; to M.I.C.). A.U. received funding from Spanish Ministry of Science and Innovation, and A.R.-A. from Red de Trastornos Adictivos.

Disclosures
None.

References

Downloaded from http://stroke.ahajournals.org/ by guest on November 18, 2017


Apolipoprotein-E Controls Adenosine Triphosphate-Binding Cassette Transporters ABCB1 and ABCC1 on Cerebral Microvessels After Methamphetamine Intoxication

Stroke. 2012;43:1647-1653; originally published online March 15, 2012;
doi: 10.1161/STROKEAHA.111.648923
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/43/6/1647

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2012/03/15/STROKEAHA.111.648923.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
Supplementary Materials and Methods

Antibodies

The following antibodies were used for the Western blotting and immunoprecipitation studies: Antibodies against ApoE (sc-6385), ABCB1 (sc-8313), claudin-5 (sc-28670), VCAM-1 (sc-8304), β-tubulin (sc-9104) and phospho-tyrosine (PY20; sc-508) were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Antibodies against total JNK1/2 (9252), phosphorylated JNK1/2^Thr183/Tyr185 (9255), total c-Jun (9165), phosphorylated c-Jun^Ser63 (9261), total p38 mitogen-activated protein kinase (MAPK) (9212), phospho-p38 MAPK^Thr180/Tyr182 (9211) and β-actin (4967) were obtained from Cell Signaling (Danvers, MA, U.S.A.). The antibody against occludin was from Invitrogen (71-1500), the antibody against ApoER2 (ab52905) from Abcam (Cambridge, UK), the antibody against ICAM-1 (BAF796) from R&D systems (Wiesbaden-Nordenstadt, Germany), and the antibody against ABCC1 (ALX-801-007-c250) from Alexis Biochemicals (San Diego, CA, U.S.A.).
Legends to Supplementary Figures

Suppl. Fig. 1. Methamphetamine increases rectal temperature that is not affected by the ApoER2 inhibitor RAP and the inducible NO synthase (iNOS) inhibitor 1400W. Rectal temperature was continuously monitored during the experiments. Data are means±SD (n=5-10 animals/group). **p<0.01 for Meth compared with vehicle; ††p<0.01 for Meth/ RAP compared with vehicle; ‡‡p<0.01 for Meth/ 1400W compared with vehicle. Note the absence of differences in rectal temperature between the Meth, Meth/ RAP and Meth/ 1400W groups.

Suppl. Fig. 2. Methamphetamine increases occludin and claudin-5 expression in cerebral microvessels, and does not provoke IgG extravasation. (A, B) Western blot analysis using brain capillary extracts demonstrating that occludin and claudin-5 are increased at 3 hours after Meth exposure. Note that occludin and claudin-5 levels returned to baseline values after 24 hours. (C) Western blot analysis using total brain extracts showing absence of extravasated IgG in the brain parenchyma after Meth exposure. Ischemic tissue from mice submitted to 30 min middle cerebral artery occlusion followed by 24 hours reperfusion was used as positive control. (D) Hematoxylin-eosin staining showing the absence of any changing in the macroscopical structure of cerebral microvessels. Data are means±SD (n=4 Western blots). *p<0.05/ **p<0.01 compared with vehicle.

Suppl. Fig. 3. Leukocyte infiltration is not increased upon Meth exposure. Immunohistochemistry for leukocyte marker CD45 showing negligible changes of brain leukocyte infiltration after Meth exposure. A representative microphotograph is also shown. Data are means±SD (n=5 animals/group). No significant differences between groups were found.
Suppl. Fig. 4. The ApoER2 inhibitor RAP and inducible NO synthase (iNOS) inhibitor 1400W alone do not affect ABB1 and ABCC1 expression. (A, B) Western blot analysis using brain capillary extracts demonstrating that (A) ABCB1, and (B) ABCC1 expression do not differ among otherwise healthy mice that received either vehicle, RAP or 1400W 3 hours before. Data are means±SD (n=4 animals/group). No significant differences between groups were found.
Supplementary Figure 4

A) Western blot for β-tubulin and ABCB1 with Vehicle, RAP, and 1400W treatments.

B) Western blot for β-tubulin and ABCC1 with Vehicle, RAP, and 1400W treatments.

Graphs showing the percentage of control for each treatment group with error bars.
**Supplementary Table.** Mean arterial blood pressure (in mmHg) in mice receiving methamphetamine (Meth) injections

<table>
<thead>
<tr>
<th>Time-point</th>
<th>Group</th>
<th>- 6 - 0 min</th>
<th>0 - 6 min</th>
<th>6 - 12 min</th>
<th>12 - 18 min</th>
<th>18-24 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>First injection</td>
<td>Vehicle</td>
<td>77.1±5.3</td>
<td>74.1±3.5</td>
<td>73.5±4.2</td>
<td>72.6±5.1</td>
<td>71.1±5.3</td>
</tr>
<tr>
<td></td>
<td>Meth</td>
<td>83.2±6.7</td>
<td>80.1±11.2</td>
<td>79.9±12.3</td>
<td>78.3±12.2</td>
<td>77.6±11.7</td>
</tr>
<tr>
<td>Second injection</td>
<td>Vehicle</td>
<td>70.3±8.1</td>
<td>67.7±8.4</td>
<td>68.1±11.5</td>
<td>67.9±9.8</td>
<td>67.9±10.6</td>
</tr>
<tr>
<td></td>
<td>Meth</td>
<td>65.3±4.1</td>
<td>65.3±11.7</td>
<td>67.0±6.1</td>
<td>69.6±8.4</td>
<td>69.9±4.3</td>
</tr>
<tr>
<td>Third injection</td>
<td>Vehicle</td>
<td>68.1±8.0</td>
<td>68.8±9.2</td>
<td>67.5±7.7</td>
<td>67.3±7.4</td>
<td>67.1±7.1</td>
</tr>
<tr>
<td></td>
<td>Meth</td>
<td>57.6±2.2</td>
<td>56.1±3.2</td>
<td>55.7±2.5</td>
<td>58.7±7.4</td>
<td>56.8±4.7</td>
</tr>
<tr>
<td>24 hours later</td>
<td>Vehicle</td>
<td>81.1±12.7</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Meth</td>
<td>76.9±14.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

No significant differences between groups. Data are means±SD (n=4-5 mice/group).

NA, not applicable.